| Literature DB >> 26410239 |
Romana Hadravová1, Michaela Rumlová2, Tomáš Ruml3.
Abstract
Due to the high number of drug-resistant HIV-1 mutants generated by highly active antiretroviral therapy (HAART), there is continuing demand for new types of inhibitors. Both the assembly of the Gag polyprotein into immature and mature HIV-1 particles are attractive candidates for the blocking of the retroviral life cycle. Currently, no therapeutically-used assembly inhibitor is available. One possible explanation is the lack of a reliable and simple assembly inhibitor screening method. To identify compounds potentially inhibiting the formation of both types of HIV-1 particles, we developed a new fluorescent high-throughput screening assay. This assay is based on the quantification of the assembly efficiency in vitro in a 96-well plate format. The key components of the assay are HIV-1 Gag-derived proteins and a dual-labelled oligonucleotide, which emits fluorescence only when the assembly of retroviral particles is inhibited. The method was validated using three (CAI, BM2, PF74) reported assembly inhibitors.Entities:
Keywords: Assay; Assembly; CA; Capsid; HIV; High-throughput screening; Inhibitor; Retrovirus
Mesh:
Substances:
Year: 2015 PMID: 26410239 DOI: 10.1016/j.virol.2015.08.029
Source DB: PubMed Journal: Virology ISSN: 0042-6822 Impact factor: 3.616